Despite major advances in targeted therapy for ALK+ metastatic non-small cell lung cancer (mNSCLC), challenges remain in achieving durable responses and preventing treatment resistance. Hear from Dr. Alice Shaw as she explores key unanswered questions and emerging research aimed at addressing gaps in care for these patients. Dr. Shaw is the Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School.
Podden och tillhörande omslagsbild på den här sidan tillhör
ReachMD. Innehållet i podden är skapat av ReachMD och inte av,
eller tillsammans med, Poddtoppen.
